igf 1 lr3 achat IGF1 | IGF1 Peptide | Recombinant Human IGF-1 LR3 – Research Peptide

discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data

Community protocols describe swirling gently (not shaking), followed by refrigeration at 28C

Other emerging non-canonical regulators include the mevalonate pathway, which generates coenzyme Q10 (CoQ10), an essential cofactor for FSP1

Research published in Growth Hormone & IGF Research demonstrates that the growth hormone secretagogue ipamorelin counteracts the catabolic effects of glucocorticoids on skeletal muscles

PSPeptides also carries tesamorelin for researchers who want the most clinically validated GHRH compound